{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:05:49Z","timestamp":1784199949755,"version":"3.55.0"},"reference-count":69,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The therapeutic landscape of adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is undergoing a paradigm shift, driven by the development of immunotherapy-based \u201cchemo-free\u201d and \u201cchemo-light\u2019 regimens. These strategies aim to achieve high efficacy with reduced toxicity, particularly in older adults who may not tolerate intensive chemotherapy. In Philadelphia chromosome-positive (Ph+) BCP-ALL, the incorporation of ABL tyrosine kinase inhibitors (TKIs) with blinatumomab (CD3\/CD19 bispecific T-cell engager) has shown remarkable efficacy, with some studies reporting molecular response rates in the range of 90\u2013100% and long-term survival exceeding 80% without the need for intensive chemotherapy or allogeneic hematopoietic cell transplantation (allo-HCT). In Philadelphia-negative (Ph\u2212) BCP- ALL, an immunotherapy-based combination of blinatumomab and inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate) has demonstrated high rates of complete remission and measurable residual disease (MRD) negativity, with manageable toxicity. While chimeric antigen receptor (CAR) T-cell therapy remains a transformative option for relapsed\/refractory B-ALL, its integration into frontline treatment is still under investigation. Ongoing trials are evaluating the optimal sequencing and combinations of these agents and their potential to obviate the need for chemotherapy and\/or allo-HCT in selected patients. As evidence continues to accumulate, chemo-free and chemo-light regimens, incorporating minimal chemotherapy with targeted agents to balance efficacy and reduced toxicity, are poised to redefine the standard of care for adults BCP-ALL, offering the possibility of durable remissions with reduced treatment-related morbidity.<\/jats:p>","DOI":"10.3390\/cancers17172746","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:09:32Z","timestamp":1756080572000},"page":"2746","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"17","author":[{"given":"Moazzam","family":"Shahzad","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-7339","authenticated-orcid":false,"given":"Muhammad Kashif","family":"Amin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: State-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.2023022921","article-title":"Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia","volume":"145","author":"Badar","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25229","article-title":"Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens","volume":"93","author":"Siegel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_7","first-page":"103392","article-title":"Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era","volume":"71","author":"Badar","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/hematology.2021000226","article-title":"Acute lymphoblastic leukemia in older adults: Curtain call for conventional chemotherapy?","volume":"2021","author":"Luskin","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2012-07-379016","article-title":"How I treat older patients with ALL","volume":"122","year":"2013","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome\u2013Negative B-Cell Acute Lymphoblastic Leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome\u2013Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","volume":"42","author":"Bassan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: A US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_18","first-page":"e247065","article-title":"The Role of CAR T-Cell Therapy in Relapsed\/Refractory Adult B-ALL","volume":"22","author":"Othman","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-020-0706-6","article-title":"Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"21","author":"Badar","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","article-title":"CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease","volume":"70","author":"Lu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: A phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e08838b08837","DOI":"10.1097\/01.HS9.0000967380.08838.b7","article-title":"S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, PH-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"7","author":"Wieduwilt","year":"2023","journal-title":"HemaSphere"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428190902943077","article-title":"Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab","volume":"50","author":"Nagorsen","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Zugmaier","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: Real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: The GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: A single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Brissot","year":"2022","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: Long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2023-173551","article-title":"Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study","volume":"142","author":"Geyer","year":"2023","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2023-180204","article-title":"Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)","volume":"142","author":"Advani","year":"2023","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000539391","article-title":"A Multicentre, Randomized Trial in Adults with de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess the Efficacy of Ponatinib versus Imatinib in Combination with Low-Intensity Chemotherapy, to Compare End of Therapy with Indication for Stem Cell Transplantation versus Tyrosine Kinase Inhibitor, Blinatumomab, and Chemotherapy in Optimal Responders, and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE)","volume":"47","author":"Lang","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2023-186139","article-title":"Frontline Combination of 3 rd Generation TKI Olverembatinib and Blinatumomab for Ph+\/Ph-like ALL Patients","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/JCO.2025.43.16_suppl.6509","article-title":"A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults","volume":"43","author":"Luskin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","unstructured":"(2025, June 06). ClinicalTrials.gov. Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT04530565."},{"key":"ref_52","unstructured":"(2025, June 06). ClinicalTrials.gov. Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04722848."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: A phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Song, Y., Chen, S., Liu, C., Chen, L., Wang, W., Wu, B., and Liang, Y. (2023). Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1051305"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/bloodadvances.2020002403","article-title":"Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia","volume":"4","author":"Cassaday","year":"2020","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2021-152927","article-title":"Tandem CD19\/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia Patients","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Li, L., Wang, L., Liu, Q., Wu, Z., Zhang, Y., and Xia, R. (2022). Efficacy and safety of CD22-specific and CD19\/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.954345"},{"key":"ref_66","unstructured":"(2025, August 11). ClinicalTrials.gov. Daratumumab for MRD-Positive Acute Lymphoblastic Leukemia, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03808610."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wang, S., Zhang, D., He, X., Wang, X., Han, H., and Qin, Y. (2023). Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1230893"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2746\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:40Z","timestamp":1760034880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":69,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172746"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172746","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]}}}